Discordance between hormone receptor profile of primary breast cancer and metastatic bone disease: should bone marrow biopsy be considered a standard of care?

被引：0
|
作者：
Amir, E. [1 ]
Broom, R. [1 ]
Freedman, O. [1 ]
Ooi, W. S. [1 ]
Done, S. [2 ]
Gianfelice, D. [3 ]
Barth, D. [1 ]
Kahn, H. [4 ]
Clemons, M. [1 ]
机构：
[1] Princess Margaret Hosp, Div Hematol & Med Oncol, Toronto, ON M4X 1K9, Canada
[2] Univ Hlth Network, Dept Pathol, Toronto, ON, Canada
[3] Univ Hlth Network, Dept Intervent Radiol, Toronto, ON, Canada
[4] Sunnybrook Med Ctr, Dept Pathol, Toronto, ON, Canada
来源：
BREAST CANCER RESEARCH | 2009年 / 11卷
关键词：
Breast Cancer; Estrogen Receptor; Progesterone Receptor; Bone Metastasis; Receptor Status;
D O I：
10.1186/bcr2310
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S18 / S18
页数：1
相关论文
共 50 条
  • [41] Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study
    Mark J. Clemons
    Brandy Cochrane
    Gregory R. Pond
    Nadia Califaretti
    Stephen K. L. Chia
    Rebecca Alexandra Dent
    Xinni Song
    Andre Robidoux
    Sameer Parpia
    David Warr
    Daniel Rayson
    Kathleen I. Pritchard
    Mark N. Levine
    Breast Cancer Research and Treatment, 2014, 146 : 153 - 162
  • [42] Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study
    Clemons, Mark J.
    Cochrane, Brandy
    Pond, Gregory R.
    Califaretti, Nadia
    Chia, Stephen K. L.
    Dent, Rebecca Alexandra
    Song, Xinni
    Robidoux, Andre
    Parpia, Sameer
    Warr, David
    Rayson, Daniel
    Pritchard, Kathleen I.
    Levine, Mark N.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (01) : 153 - 162
  • [43] Exploring the relationships between hormone receptor, HER2 status, and bone involvement in the first distant metastases of in Chinese breast cancer patients who lacked HER2 targeted therapy
    Jia, Zhifeng
    Dai, Muwei
    Shang, Yuguang
    Li, Yue
    Li, Zhensheng
    BMC CANCER, 2023, 23 (01)
  • [44] Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer
    Jeong, Hyehyun
    Jeong, Jae Ho
    Kim, Jeong Eun
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Koh, Su-Jin
    Cheon, Jaekyung
    Sohn, Joohyuk
    Kim, Gun Min
    Lee, Keun Seok
    Sim, Sung Hoon
    Park, In Hae
    Kim, Sung-Bae
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (04) : 917 - 924
  • [45] Exploring the relationships between hormone receptor, HER2 status, and bone involvement in the first distant metastases of in Chinese breast cancer patients who lacked HER2 targeted therapy
    Zhifeng Jia
    Muwei Dai
    Yuguang Shang
    Yue Li
    Zhensheng Li
    BMC Cancer, 23
  • [46] Detection of disseminated tumor cells in the bone marrow of breast cancer patients using multiplex gene expression measurements identifies new therapeutic targets in patients at high risk for the development of metastatic disease
    Chidananda M. Siddappa
    Mark A. Watson
    Sreeraj G. Pillai
    Kathryn Trinkaus
    Timothy Fleming
    Rebecca Aft
    Breast Cancer Research and Treatment, 2013, 137 : 45 - 56
  • [47] Detection of disseminated tumor cells in the bone marrow of breast cancer patients using multiplex gene expression measurements identifies new therapeutic targets in patients at high risk for the development of metastatic disease
    Siddappa, Chidananda M.
    Watson, Mark A.
    Pillai, Sreeraj G.
    Trinkaus, Kathryn
    Fleming, Timothy
    Aft, Rebecca
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (01) : 45 - 56
  • [48] Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
    Rugo, Hope S.
    Van Poznak, Catherine H.
    Neven, Patrick
    Danielewicz, Iwona
    Lee, Soo Chin
    Campone, Mario
    Chik, Jeannie Y. K.
    Alonso, Estela Vega
    Naume, Bjorn
    Brain, Etienne
    Siegel, Jonathan M.
    Li, Rui
    Uema, Deise
    Wagner, Volker J.
    Coleman, Robert E.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (02) : 249 - 259
  • [49] Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
    Hope S. Rugo
    Catherine H. Van Poznak
    Patrick Neven
    Iwona Danielewicz
    Soo Chin Lee
    Mario Campone
    Jeannie Y. K. Chik
    Estela Vega Alonso
    Bjørn Naume
    Etienne Brain
    Jonathan M. Siegel
    Rui Li
    Deise Uema
    Volker J. Wagner
    Robert E. Coleman
    Breast Cancer Research and Treatment, 2024, 204 : 249 - 259
  • [50] Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer
    Ina H Benoy
    Roberto Salgado
    Hilde Elst
    Peter Van Dam
    Joost Weyler
    Eric Van Marck
    Simon Scharpé
    Peter B Vermeulen
    Luc Y Dirix
    Breast Cancer Research, 7
12345